Impact of genetic factors on platinum-induced gastrointestinal toxicity

Mutat Res Rev Mutat Res. 2020 Oct-Dec:786:108324. doi: 10.1016/j.mrrev.2020.108324. Epub 2020 Jul 16.

Abstract

Severe gastrointestinal (GI) toxicity is a common side effect after platinum-based chemotherapy. The incidence and severity of GI toxicity vary among patients with the same chemotherapy. Genetic factors involved in platinum transport, metabolism, detoxification, DNA repair, cell cycle control, and apoptosis pathways may account for the interindividual difference in GI toxicity. The influence of gene polymorphisms in the platinum pathway on GI toxicity has been extensively analyzed. Variations in study sample size, ethnicity, design, treatment schedule, dosing, endpoint definition, and assessment of toxicity make it difficult to precisely interpret the results. Hence, we conducted a review to summarize the most recent pharmacogenomics studies of GI toxicity in platinum-based chemotherapy and identify the most promising avenues for further research.

Keywords: Gastrointestinal toxicity; Pathogenesis; Pharmacogenomics; Platinum; Polymorphisms.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents / toxicity*
  • DNA Repair
  • Drug Therapy
  • Drug-Related Side Effects and Adverse Reactions / genetics*
  • Gastrointestinal Tract / drug effects*
  • Genotype
  • Humans
  • Pharmacogenetics*
  • Pharmacogenomic Testing
  • Phenotype
  • Platinum / toxicity*
  • Polymorphism, Genetic*

Substances

  • Antineoplastic Agents
  • Platinum